Bridges K R, Cudkowicz A
J Biol Chem. 1984 Nov 10;259(21):12970-7.
Delivery of iron to K562 cells by diferric transferrin involves a cycle of binding to surface receptors, internalization into an acidic compartment, transfer of iron to ferritin, and release of apotransferrin from the cell. To evaluate potential feedback effects of iron on this system, we exposed cells to iron chelators and monitored the activity of the transferrin receptor. In the present study, we found that chelation of extracellular iron by the hydrophilic chelators desferrioxamine B, diethylenetriaminepentaacetic acid, or apolactoferrin enhanced the release from the cells of previously internalized 125I-transferrin. Presaturation of these compounds with iron blocked this effect. These chelators did not affect the uptake of iron from transferrin. In contrast, the hydrophobic chelator 2,2-bipyridine, which partitions into cell membranes, completely blocked iron uptake by chelating the iron during its transfer across the membrane. The 2,2-bipyridine did not, however, enhance the release of 125I-transferrin from the cells, indicating that extracellular iron chelation is the key to this effect. Desferrioxamine, unlike the other hydrophilic chelators, can enter the cell and chelate an intracellular pool of iron. This produced a parallel increase in surface and intracellular transferrin receptors, reaching 2-fold at 24 h and 3-fold at 48 h. This increase in receptor number required ongoing protein synthesis and could be blocked by cycloheximide. Diethylenetriaminepentaacetic acid or desferrioxamine presaturated with iron did not induce new transferrin receptors. The new receptors were functionally active and produced an increase in 59Fe uptake from 59Fe-transferrin. We conclude that the transferrin receptor in the K562 cell is regulated in part by chelatable iron: chelation of extracellular iron enhances the release of apotransferrin from the cell, while chelation of an intracellular iron pool results in the biosynthesis of new receptors.
双铁运铁蛋白将铁传递给K562细胞的过程包括与表面受体结合、内化进入酸性区室、将铁转移至铁蛋白以及脱铁运铁蛋白从细胞释放的循环。为了评估铁对该系统的潜在反馈作用,我们将细胞暴露于铁螯合剂中并监测转铁蛋白受体的活性。在本研究中,我们发现亲水性螯合剂去铁胺B、二乙烯三胺五乙酸或脱铁乳铁蛋白对细胞外铁的螯合增强了先前内化的125I-转铁蛋白从细胞中的释放。这些化合物用铁预饱和可阻断此效应。这些螯合剂不影响从转铁蛋白摄取铁。相反,疏水性螯合剂2,2-联吡啶可分配到细胞膜中,通过在铁跨膜转运过程中螯合铁而完全阻断铁摄取。然而,2,2-联吡啶并未增强125I-转铁蛋白从细胞中的释放,表明细胞外铁螯合是此效应的关键。与其他亲水性螯合剂不同,去铁胺可进入细胞并螯合细胞内的铁池。这导致表面和细胞内转铁蛋白受体平行增加,在24小时时达到2倍,在48小时时达到3倍。受体数量的这种增加需要持续的蛋白质合成,并且可被环己酰亚胺阻断。用铁预饱和的二乙烯三胺五乙酸或去铁胺不会诱导新的转铁蛋白受体。新受体具有功能活性,并导致从59Fe-转铁蛋白摄取59Fe增加。我们得出结论,K562细胞中的转铁蛋白受体部分受可螯合铁的调节:细胞外铁的螯合增强了脱铁运铁蛋白从细胞中的释放,而细胞内铁池的螯合导致新受体的生物合成。